Among daily cannabis consumers aged 18–35, about 56% reported lifetime psychedelic use, with psilocybin most common (50%), followed by LSD (29%) and DMT (3.5%). Overall, 33% had subthreshold insomnia, 3.2% moderate-severity clinical insomnia, and 1.6% severe clinical insomnia. LSD and DMT were associated with moderate-to-severe clinical insomnia: 17.7% of LSD users vs. 0.0% of non-users, and 50.0% of DMT users vs. 3.6% of non-users. Psilocybin showed no significant association. LSD users also reported more frequent sleep-related interference with daily functioning. No differences were found in cannabis use for sleep or demographics by psychedelic use.
Among 18-to-35-year-olds in the Herbal Heart Study, 39.5% reported lifetime psychedelic use and 32.8% reported psilocybin use. Overall, 54.5% were satisfied with sleep, 23.0% dissatisfied, and 22.5% neutral, with no differences in sleep satisfaction across the full sample. However, among Hispanic/Latino participants, 33.9% of psychedelic consumers reported sleep dissatisfaction versus 17.2% of non-consumers. Hispanic/Latino psychedelic consumers had 4.4 times higher odds of both sleep dissatisfaction and satisfaction compared to being neutral; psilocybin-alone consumers had 9.2 times higher odds of dissatisfaction. No associations appeared among non-Hispanic White, non-Hispanic Black, or other groups, suggesting a complex link specific to Hispanic/Latino individuals.